Approve the CMS Rule

America’s patients are needlessly spending too much out-of-pocket for affordable generics. CMS can lower costs by 4 billion dollars a year by placing generics on the generics tier.

Learn More
Prescription for Savings

Congress can take meaningful action to lower prescription drug costs for patients who rely on affordable medicines to live healthy lives.

Learn More
State-by-State Savings

To view a full break down of generic savings by state and payer type, view our interactive U.S. map.

View Map
Generic Drugs are the Prescription for Savings

More than 9 out of 10 generic drug prescriptions are filled for $20 or less.

View Infographic
Preserve Patient Access in Trade Agreements

The new trade agreement (USMCA) keeps drug prices high, for longer and creates new barriers to competition from generics and biosimilars. Without action, drug prices will remain out of reach for Americans.

Learn More

Working to leave a positive impact on...

Industry

We promote competition in the pharmaceutical industry by lowering barriers to entry for manufacturers and combatting anti-competitive abuses by some brand drug companies who put profits before patients. Learn More

People

We measure our success as an industry by the lives we impact. We work to protect the low cost of current drugs and to drive down the cost of developing new ones, expanding access to as many people as possible. Learn More

Society

We are a trusted partner and established authority within the pharmaceutical field. We provide accurate, timely data to educate policymakers and promote general public knowledge regarding the positive impact of affordable medicines. Learn More

About Us

The Association for Accessible Medicines, formerly the Generic Pharmaceutical Association, improves access to safe, quality, effective medicine. Better access to medicine is relevant to everybody because, after all, we’re all patients at some point.

Health is the foundation for everything in life. Healthy people are better able to reach their full potential. Generics and biosimilars help more people in more places live healthier and longer.

Recent Updates

Karin Hessler Joins AAM as Assistant General Counsel

Mar 18, 2019 | Rachel Schwartz

Karin Hessler Joins AAM as Assistant General Counsel

AAM Statement in Response to Administration's FY 2020 Budget Proposal

Mar 11, 2019 | Rachel Schwartz

AAM Statement in Response to Administration's FY 2020 Budget Proposal

Healthcare Leadership Luncheon sponsored by Mylan N.V. and powered by Women in Health Policy (WiHP)

Mar 11, 2019 | Anna McDermott-Vitak

Talking Female Leadership at Access! 2019

AAM Statement on FDA Draft Guidance on Biosimilar Naming Requirements

Mar 7, 2019 | Rachel Schwartz

AAM Statement on FDA Draft Guidance on Biosimilar Naming Requirements

Mar 5, 2019 | Rachel Schwartz

AAM Statement on Dr. Scott Gottlieb's Departure

AAM Statement on Avalere Report

Feb 28, 2019 | Rachel Schwartz

New Study Shows Seniors Paid Nearly $22 Billion in Extra Out-of-Pocket Costs for Generic Medicines